TY - JOUR
T1 - Neurologist-associated reduction in PD-related hospitalizations and health care expenditures
AU - Willis, Allison W.
AU - Schootman, Mario
AU - Pollard, Rebecca
AU - Kung, Nathan
AU - Evanoff, Bradley A.
AU - Perlmutter, Joel S.
AU - Racette, Brad A.
N1 - Funding Information:
Study funding: Supported primarily by the National Center for Research Resources and National Institutes of Health Roadmap for Medical Research (UL1RR024992, KL2RR024994). Other support: National Institute of Neurological Disorders and Stroke at the National Institutes of Health (5T32NS007205–27); the St. Louis Chapter of the American Parkinson Disease Association; the American Parkinson Disease Association, Walter and Connie Donius; and the Robert Renschen Fund.
Funding Information:
A. Willis receives research support from the NIH, the American Parkinson Disease Association, St. Louis Chapter, Walter and Connie Donius, and The Robert Renschen Fund. M. Schootman receives research support from the NIH. R. Tran and N. Kung report no disclosures. B. Evanoff receives support from the NIH and has served as a paid consultant for Monsanto and Concentra Health Care. J. Perlmutter serves on the scientific advisory boards of the American Parkinson Disease Association, Dystonia Medical Research Foundation, Missouri Chapter of the Dystonia Medical Research Fund, and Greater St. Louis Chapter of the APDA; serves as an editorial board member of Neurology®; received honoraria from Ceregene for travel to lecture; received honoraria from Parkinson Disease Study Group for grant reviews; received partial fellowship support for fellows from Medtronic Inc; and receives research support from the NIH, the Huntington Disease Society of American Center of Excellence, Michael J. Fox Foundation, HiQ Foundation, McDonnell Center for Higher Brain Function, Greater St. Louis Chapter of the American Parkinson Disease Association, American Parkinson Disease Association, Bander Foundation for Medical Ethics and Advanced PD Research Center at Washington University, and the Barnes Jewish Hospital Foundation. B. Racette received research support from Teva, Eisai, and Solvay; receives research support from Schwarz, Solstice, Eisai, Allergan, and Neurogen; and received research support from the NIH, BJHF/ICTS [Neuropathology of Chronic Manganese Exposure” (PI)], and the Michael J. Fox Foundation. Go to Neurology.org for full disclosures.
PY - 2012/10/23
Y1 - 2012/10/23
N2 - Objective: To investigate the impact of neurologist care on Parkinson disease (PD)-related hospitalizations. Recent data indicate that neurologist treatment in PD may be associated with improved survival, yet is underutilized. Factors contributing to this improved survival remain unknown, but may be due in part to optimal disease treatment or avoidance of disease-related complications. Methods: This was a retrospective cohort study of Medicare beneficiaries diagnosed with PD in 2002 and still living in 2006. Hospitalization for PD-related (neurodegenerative disease, psychosis, depression, urinary tract infection, and traumatic injury) and general medical (hypertension, diabetes, congestive heart failure, angina, and gastrointestinal obstruction) illnesses was compared by PD treating physician specialty using Cox proportional hazard models, adjusting for confounders. Secondary analyses included PD-related rehospitalization and cost stratified by frequency of neurologist care. Results: We identified 24,929 eligible incident PD cases; 13,489 had neurologist care. There were 9,112 PD-related hospitalizations, and these occurred and recurred less often among neurologist-treated patients. Neurologist PD care was associated with lower adjusted odds of both initial and repeat hospitalization for psychosis (hazard ratio [HR] 0.71, 95% confidence interval [CI] 0.59-0.86), urinary tract infection (HR 0.74, 0.63-0.87), and traumatic injury (HR 0.56, 0.40-0.78). PD-related outcomes improved with frequency of neurologist care in a stepwise manner. Odds of general illness hospitalization or hospitalization did not differ by neurologist involvement. Conclusions: Regular neurologist care in PD is specifically associated with lower risk of hospitalization and rehospitalization for several PD-related illnesses. This may reflect an improved ability of neurologists to prevent, recognize, or treat PD complications.
AB - Objective: To investigate the impact of neurologist care on Parkinson disease (PD)-related hospitalizations. Recent data indicate that neurologist treatment in PD may be associated with improved survival, yet is underutilized. Factors contributing to this improved survival remain unknown, but may be due in part to optimal disease treatment or avoidance of disease-related complications. Methods: This was a retrospective cohort study of Medicare beneficiaries diagnosed with PD in 2002 and still living in 2006. Hospitalization for PD-related (neurodegenerative disease, psychosis, depression, urinary tract infection, and traumatic injury) and general medical (hypertension, diabetes, congestive heart failure, angina, and gastrointestinal obstruction) illnesses was compared by PD treating physician specialty using Cox proportional hazard models, adjusting for confounders. Secondary analyses included PD-related rehospitalization and cost stratified by frequency of neurologist care. Results: We identified 24,929 eligible incident PD cases; 13,489 had neurologist care. There were 9,112 PD-related hospitalizations, and these occurred and recurred less often among neurologist-treated patients. Neurologist PD care was associated with lower adjusted odds of both initial and repeat hospitalization for psychosis (hazard ratio [HR] 0.71, 95% confidence interval [CI] 0.59-0.86), urinary tract infection (HR 0.74, 0.63-0.87), and traumatic injury (HR 0.56, 0.40-0.78). PD-related outcomes improved with frequency of neurologist care in a stepwise manner. Odds of general illness hospitalization or hospitalization did not differ by neurologist involvement. Conclusions: Regular neurologist care in PD is specifically associated with lower risk of hospitalization and rehospitalization for several PD-related illnesses. This may reflect an improved ability of neurologists to prevent, recognize, or treat PD complications.
UR - http://www.scopus.com/inward/record.url?scp=84871239509&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e3182703f92
DO - 10.1212/WNL.0b013e3182703f92
M3 - Article
C2 - 23054239
AN - SCOPUS:84871239509
SN - 0028-3878
VL - 79
SP - 1774
EP - 1780
JO - Neurology
JF - Neurology
IS - 17
ER -